GENFLEET-B (02595) announced that, based on the quarterly review results released by Hang Seng Indexes Company Limited on February 13, 2026, the company has been selected as a constituent of the Hang Seng Composite Index (HSCI), the Hang Seng Stock Connect Hong Kong Index, and the Hang Seng Innovative Medicine Index, among other series. These changes will take effect on March 9, 2026. Additionally, following the recent quarterly review announcement by MSCI, the company will also be included in the MSCI Global Small Cap Index, with this adjustment effective after the market close on February 27, 2026. The Hang Seng Composite Index serves as a comprehensive benchmark for the Hong Kong market, covering the top 95% of listed companies by cumulative market capitalization on the Main Board of The Stock Exchange of Hong Kong. It is widely used as a benchmark for index funds, mutual funds, and investment performance evaluation. Inclusion in the Hang Seng Composite Index will make the company's shares eligible for trading through the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, which facilitate share trading between investors in Hong Kong and Mainland China. According to the review results from Hang Seng Indexes Company Limited, the company will also be added to several other Hang Seng Index series, including the Hang Seng Composite MidCap & SmallCap Index, the Hang Seng Composite SmallCap Index, the Hang Seng SmallCap (Investable) Index, the Hang Seng Stock Connect Hong Kong Mainland Companies Index, the Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, the Hang Seng Stock Connect Hong Kong SmallCap Index, the Hang Seng Stock Connect Hong Kong Innovative Medicine Index, the Hang Seng Stock Connect Hong Kong Innovative Medicine Select Index, the Hang Seng Stock Connect Hong Kong Pharmaceuticals & Biotechnology (Investable) Index, the Hang Seng Composite Industry Index - Healthcare, and the Hang Seng Healthcare Index. The Board of Directors believes that the inclusion of the company's shares in these major indices reflects investor recognition of the company's value and growth potential. It is expected to enhance the stock's liquidity, broaden the shareholder base, increase the diversity of shareholder types, and benefit the company's long-term stable development. The Board expressed gratitude to shareholders and investors for their ongoing support. The company will continue to deepen its leading advantages in the RAS field and strengthen its international competitiveness in other innovative drug areas. It aims to drive contemporary industrial value creation through its established R&D strengths, achieving synergistic wins in market development and social responsibility.